Loading...
Keywords
Last Name
Institution

Jonathan B. Wagner, DO

TitlePhysician and Interim Division Director, Clinical Pharmacology, Toxicology & Therapeutic Innovation
InstitutionChildren's Mercy Kansas City
DepartmentPediatrics
Address2401 Gilham Rd
Kansas City MO 64108
vCardDownload vCard
    Other Positions
    TitleAssociate Professor of Pediatrics
    InstitutionUniversity of Missouri-Kansas City
    DepartmentPediatrics


    Collapse Biography 
    Collapse education and training
    Kansas City University of Medicine and Biosciences, Kansas City, MODO2007
    Children’s Mercy Hospital and Clinics, Kansas City, MOInternsip2008Pediatrics
    Children’s Mercy Hospital and Clinics, Kansas City, MOResidency2010Pediatrics
    Penn State Milton S. Hershey Medical Center, Hershey, PAFellowship2011Pediatric Cardiology
    Children’s Mercy Hospital and Clinics, Kansas City, MO Fellowship2013Pediatric Cardiology
    Children’s Mercy Hospital and Clinics, Kansas City, MOFellowship2014Pediatric Clinical Pharmacology

    Collapse Overview 

    Collapse Research 
    Collapse research overview
    Jonathan Wagner, DO, FAAP, graduated with a bachelor of science degree in biochemistry with cum laude latin honors from the University of Missouri-Columbia and received his medical degree with magna cum laude honors from Kansas City University of Medicine and Biosciences. He completed pediatrics residency at Children’s Mercy, followed by a dual fellowship training in pediatric cardiology and pediatric clinical pharmacology. Dr. Wagner joined our faculty in 2013. His early career research involved the impact of genetic variation and development on statin disposition during childhood. His series of pharmacogenomics driven pharmacokinetic studies involving statins has contributed to further understanding of inter-individual variability of statin response in the pediatric population. Dr. Wagner has served as a site-primary investigator for the Fontan Udenafil Exercise Longitudinal (FUEL) and Fontan Associated Liver Disease (FALD) trials sponsored by the Pediatric Heart Network (NHLBI). He is director of the Cardiology Pharmacogenomics Repository (CPR) at Children’s Mercy Kansas City (CMKC). Dr. Wagner has been honored as a finalist for the 2016 AHA Scientific Sessions Council of Cardiovascular Disease in the Young Early Career Award and the CMKC Department of Pediatrics Research Achievement Award in 2018. He has received over 1 million dollars in external funding from the American Heart Association, Thrasher Research Fund, and the National Institutes of Health (NIH) to support his research programs involving pediatric cardiovascular disease and pediatric clinical pharmacology. More recently, his NIH funding from the Frontiers KL2 Clinical and Transitional Mentored Career Development Award has supported his Statin Optimization in Pediatrics program. Dr. Wagner serves on the Advisory Council on Rare Disease and Personalized Medicine for Missouri Health Net division of the Missouri Department of Social Services. He is a member of the American Heart Association (AHA) Kansas City Board of Directors and remains involved in the State of Kansas AHA Advocacy Committee. He has presented at multiple local and national meetings, has over 25 peer-review publications, authored several books chapters and serves as an editorial board member of Clinical and Translational Sciences. Dr. Wagner currently serves as the Division Director of Clinical Pharmacology, Toxicology, and Therapeutic Innovation and remains an active member of the Ward Family Heart Center involved in cardiovascular intensive care, congenital heart disease and cardiovascular genetics. Dr. Wagner’s passion involves clinical integration of pharmacogenomics and precision medicine into routine cardiovascular care, but his true passion is spending quality time with his wife (Margo) and 2 boys (Oliver and Teddy) when not busy at work.
    Collapse research activities and funding
    13CRP16940091     (Wagner, Jonathan)Jul 1, 2013
    American Heart Association Midwest Affiliate Clinical Research Program
    Pharmacokinetics of pravastatin and simvastatin in pediatric dyslipidemia patients: Clinical impact of genetic variation in statin disposition
    Role Description: Award declined due to acceptance of AHA National Affiliate Grant
    Role: Primary Investigator

    Thrasher Research Fund Early Career Award Program      (Wagner, Jonathan)Jul 1, 2013
    Thrasher Research Fund
    Pharmacokinetics of pravastatin and simvastatin in pediatric dyslipidemia patients: Clinical impact of genetic variation in statin disposition
    Role Description: Award declined due to acceptance of AHA Grant
    Role: Primary Investigator

    Children’s Mercy Hospital Clinical Fellowship Rese     (Wagner, Jonathan)Jul 1, 2013 - Jun 30, 2015
    Children's Mercy Hospital
    Cardiology Pharmacogenomics Repository
    Role: Primary Investigator

    13CRP17110023     (Wagner, Jonathan)Jul 1, 2013 - Jun 30, 2016
    American Heart Association National Affiliate Clinical Research Program
    Pharmacokinetics of pravastatin and simvastatin in pediatric dyslipidemia patients: Clinical impact of genetic variation in statin disposition
    Role: Primary Investigator

    Marion Merrell Dow Clinical Scholar Award     (Wagner, Jonathan)Jul 1, 2014 - Aug 1, 2017
    Children’s Mercy Kansas City
    Pharmacokinetics of rosuvastatin and atorvastatin in pediatric dyslipidemia patients: Clinical impact of genetic variation in statin disposition
    Role: Primary Investigator

    1 U10 HL068270     (Paridon, Stephen)Jul 1, 2015 - Dec 31, 2019
    NHLBI (PHN)
    Fontan Udenafil Exercise Longitudinal (FUEL) Assessment Trial
    Role: Site Primary Investigator

    1 U10 HL068270     (Paridon, Stephen)May 1, 2017
    NHLBI (PHN)
    A Phase III Safety Extension Study of Udenafil in Adolescents with Single Ventricle Physiology after Fontan Palliation (FUEL Extension)
    Role: Site Primary Investigator

    KL2TR002367     (Wagner, Jonathan)Sep 1, 2017 - Jun 30, 2020
    NCATS (Frontiers Clinical and Translational Science Institute)
    Statin Optimization in Pediatrics
    Role: Primary Investigator

    1 U54 HD090258-02     (Leeder, J. Stephen)Apr 1, 2018 - Apr 1, 2020
    NICHD
    GOLDILOKs: Genomic- and Ontogeny-Linked Dose Individualization and cLinical Optimization for Kids
    Role Description: Pilot Project: Validation of OATP Endogenous Biomarkers in Children.
    Role: Pilot Project Primary Investigator

    1 U10 HL068270     (Wagner, Jonathan)Jul 2, 2018
    NHLBI (PHN)
    Imaging and Biomarker Evaluation of Hepatic Stiffness in Children Enrolled in the Fontan Udenafil Exercise Longitudinal Study (FALD Ancillary Study)
    Role: Site Primary Investigator

    Pilot Grant     (McCoin, Colin)Jul 1, 2019
    University of Kansas Medical/Children’s Mercy Hospital
    Statin Therapy in Children: Mitochondrial and Physical Function
    Role: Co-Investigator

    Collapse Bibliography 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Wagner JB, Abdel-Rahman S, Gaedigk A, Gaedigk R, Raghuveer G, Staggs VS, Van Haandel L, Leeder JS. Impact of SLCO1B1 Genetic Variation on Rosuvastatin Systemic Exposure in Pediatric Hypercholesterolemia. Clin Transl Sci. 2020 May; 13(3):628-637. PMID: 31981411.
      View in: PubMed
    2. Goldberg DJ, Zak V, Goldstein BH, Schumacher KR, Rhodes J, Penny DJ, Petit CJ, Ginde S, Menon SC, Kim SH, Kim GB, Nowlen TT, DiMaria MV, Frischhertz BP, Wagner JB, McHugh KE, McCrindle BW, Shillingford AJ, Sabati AA, Yetman AT, John AS, Richmond ME, Files MD, Payne RM, Mackie AS, Davis CK, Shahanavaz S, Hill KD, Garg R, Jacobs JP, Hamstra MS, Woyciechowski S, Rathge KA, McBride MG, Frommelt PC, Russell MW, Urbina EM, Yeager JL, Pemberton VL, Stylianou MP, Pearson GD, Paridon SM. Results of the FUEL Trial. Circulation. 2020 Feb 25; 141(8):641-651. PMID: 31736357.
      View in: PubMed
    3. Kyler KE, Wagner J, Hosey-Cojocari C, Watt K, Shakhnovich V. Drug Dose Selection in Pediatric Obesity: Available Information for the Most Commonly Prescribed Drugs to Children. Paediatr Drugs. 2019 Oct; 21(5):357-369. PMID: 31432433.
      View in: PubMed
    4. Ogungbenro K, Wagner JB, Abdel-Rahman S, Leeder JS, Galetin A. A population pharmacokinetic model for simvastatin and its metabolites in children and adolescents. Eur J Clin Pharmacol. 2019 Sep; 75(9):1227-1235. PMID: 31172248.
      View in: PubMed
    5. Wagner JB. Children Are Not Small Adults: Specific Findings in Statin Exposure and Response in a Growing Population. Clin Pharmacol Ther. 2019 08; 106(2):278-280. PMID: 30970165.
      View in: PubMed
    6. Wagner JB, Abdel-Rahman S, Gaedigk R, Gaedigk A, Raghuveer G, Staggs VS, Kauffman R, Van Haandel L, Leeder JS. Impact of Genetic Variation on Pravastatin Systemic Exposure in Pediatric Hypercholesterolemia. Clin Pharmacol Ther. 2019 06; 105(6):1501-1512. PMID: 30549267.
      View in: PubMed
    7. McLaughlin MJ, Wagner J, Shakhnovich V, Carleton B, Leeder JS. Considerations for Implementing Precision Therapeutics for Children. Clin Transl Sci. 2019 03; 12(2):140-150. PMID: 30516322.
      View in: PubMed
    8. Wagner JB, Abdel-Rahman S, Van Haandel L, Gaedigk A, Gaedigk R, Raghuveer G, Kauffman R, Leeder JS. Impact of SLCO1B1 Genotype on Pediatric Simvastatin Acid Pharmacokinetics. J Clin Pharmacol. 2018 06; 58(6):823-833. PMID: 29469964.
      View in: PubMed
    9. Wagner JB, Knowlton JQ, Pastuszko P, Shah SS. A Rare Case of Vascular Ring and Coarctation of the Aorta in Association with CHARGE Syndrome. Tex Heart Inst J. 2017 Apr; 44(2):138-140. PMID: 28461801.
      View in: PubMed
    10. Wagner J, Abdel-Rahman SM. Pediatric Statin Administration: Navigating a Frontier with Limited Data. J Pediatr Pharmacol Ther. 2016 Sep-Oct; 21(5):380-403. PMID: 27877092.
      View in: PubMed
    11. van Haandel L, Gibson KT, Leeder JS, Wagner JB. Quantification of pravastatin acid, lactone and isomers in human plasma by UHPLC-MS/MS and its application to a pediatric pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Feb 15; 1012-1013:169-77. PMID: 26849185.
      View in: PubMed
    12. Wagner J, Abdel-Rahman SM. Oseltamivir-warfarin interaction in hypoplastic left heart syndrome: case report and review. Pediatrics. 2015 May; 135(5):e1333-6. PMID: 25917992.
      View in: PubMed
    13. Wagner J, Abdel-Rahman SM. Pediatric pharmacokinetics. Pediatr Rev. 2013 Jun; 34(6):258-69. PMID: 23729775.
      View in: PubMed
    14. Tisma-Dupanovic S, Wagner JB, Shah S, Huang DT, Moss AJ. An adolescent with possible arrhythmogenic right ventricular dysplasia and long QT syndrome: evaluation and management. Ann Noninvasive Electrocardiol. 2013 Jan; 18(1):75-8. PMID: 23347029.
      View in: PubMed
    15. Wagner J, Leeder JS. Pediatric pharmacogenomics: a systematic assessment of ontogeny and genetic variation to guide the design of statin studies in children. Pediatr Clin North Am. 2012 Oct; 59(5):1017-37. PMID: 23036242.
      View in: PubMed
    Wagner's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description